Ok I would love to scoop into the close I am going to take a hot bath. Look at BDSI.... NO LONG WALKS @3:30 pm!!!!
ya, i'm in for more than the day-trade. i think this is one for the buy-and-hold portfolio. i agree with Van that this can easily trade lower tomorrow, but the revenue growth is impressive and i imagine there isn't too much downside here.
Ocular Therapeutix, Inc. (OCUL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD 11.26+1.51 (+15.49%) As of 3:21PM EDT.
oh no!!!! Ocugen & Ocular..... CONFUSION Ocugen call volume above normal and directionally bullish 12:45 OCGN Bullish option flow detected in Ocugen with 35,266 calls trading, 1.6x expected, and implied vol increasing almost 13 points to 155.17%. Oct-21 7.5 calls and Oct-21 8 calls are the most active options, with total volume in those strikes near 10,400 contracts. The Put/Call Ratio is 0.14. Earnings are expected on November 5th.
Facebook launching live shopping events Nov. 1 Oct. 11, 2021 3:20 PM ETFacebook, Inc. (FB) Facebook (FB-0.8%) keeps chipping away at new monetization via shopping, with plans tohost daily "Live Shopping" experiences on Facebook and Instagram. The live events begin Nov. 1, and Facebook will be showcasing exclusive deals and gifts from the company's Shops for those making purchases. Brands participating in the live events include Benefit Cosmetics, Cocokind, Macy’s, Paintbox Nails, Tanya Taylor, Ulta Beauty, Vuori and Walmart, the company says.
ULTA Ulta Beauty, Inc. 383.45 +5.08 Ocugen(NASDAQ:OCGN)is trading lower in the pre-market with a ~1.4% loss amid reports of a likely delay for World Health Organization (WHO) authorization for Covaxin, the COVID-19 vaccine the company intends to launch in the U.S. in partnership with Bharath Biotech. According to Hindustan Times, the global body has sent for more technical queries to the Hyderabad-based developer, Bharath Biotech, likely delaying a potential emergency use authorization (EUA) for the vaccine. Asked about if newly posed queries will lead to a delay, a WHO official said: “No, it should not be delayed… Maybe a few weeks.”
Ocugen (OCGN) has been one of the more polarizing story stocks of 2021. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via a reverse merger with floundering biotech shell Histogenics. Ocugen had been in operation since 2013 with the goal of "develop[ing] innovative therapies to treat rare and underserved eye diseases". The company had raised $19 millionin debt and equity through the life of the company and has de minimis existing revenues today. As the below chart shows, markets had little interest in this penny stock between the closing of the reverse merger in late 2019 through late 2020. Another new COVID-19 stock! That suddenly changed on December 22, 2020 when Ocugen announcedthat they had a new agreement with India's Bharat Biotech to commercialize Bharat's COVAXIN within the United States. Since then, the stock has surged more than 2,000%, from less than $0.30 to more than $7.00 today, and currently sports a market cap of more than $1.5 billion. This seems like a VAN short